A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/-Ribavirin Adolescents and Children With Chronic HCV-Infection

Trial Profile

A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/-Ribavirin Adolescents and Children With Chronic HCV-Infection

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Ledipasvir/sofosbuvir (Primary) ; Ribavirin; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 17 Jul 2017 Planned number of patients changed from 200 to 220.
    • 21 Apr 2017 According to a Gilead Sciences, results from this study were presented at The International Liver Congress 2017.
    • 21 Apr 2017 Results published in the Gilead Sciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top